Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 10 de 10
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Melanoma Res ; 12(3): 263-70, 2002 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-12140383

RESUMO

Membrane-bound Fas ligand (FasL, Apo-1L, CD95L) induces rapid apoptosis of Fas (CD95)-sensitive cells on interaction with Fas, and is an important effector molecule of cytolytic T lymphocytes (CTLs). Melanomas are immunogenic and induce the production of specific CTLs, but are usually able to escape immune destruction. We investigated Fas expression and function in 53 cutaneous melanocytic lesions and 13 melanoma cell lines grown in vitro. Immunohistochemical analysis of Fas expression in cutaneous melanocytic lesions showed moderate to high levels of Fas in common benign melanocytic naevi, but low to undetectable levels in atypical naevi, primary (superficial spreading melanoma, nodular melanoma) and cutaneous melanoma metastases. Fluorescence-activated cell sorting (FACS) analysis of Fas expression in melanoma cell lines revealed undetectable or low levels of cell surface Fas expression in five of the 13 melanoma cell lines. Analysis of Fas signalling by quantification of cell death following exposure to recombinant FasL showed that a reduction in Fas expression results in resistance to FasL-mediated cell death. Furthermore, two of the 13 melanoma cell lines were found to be resistant to FasL-mediated cell death despite conserved Fas expression. Thus seven of the 13 melanoma cell lines were found to have impaired Fas signalling. Taken together, our results indicate that downregulation of Fas expression and resistance to Fas-mediated apoptosis are frequent in melanoma.


Assuntos
Apoptose/genética , Regulação Neoplásica da Expressão Gênica , Peptídeos e Proteínas de Sinalização Intracelular , Melanoma/metabolismo , Proteínas de Neoplasias/biossíntese , Neoplasias Cutâneas/metabolismo , Receptor fas/biossíntese , Apoptose/efeitos dos fármacos , Proteína Reguladora de Apoptosis Semelhante a CASP8 e FADD , Proteínas de Transporte/biossíntese , Proteínas de Transporte/genética , Regulação para Baixo , Proteína Ligante Fas , Humanos , Melanócitos/metabolismo , Melanoma/genética , Melanoma/imunologia , Melanoma/patologia , Melanoma/secundário , Glicoproteínas de Membrana/farmacologia , Proteínas de Neoplasias/genética , Proteínas de Neoplasias/fisiologia , Nevo Pigmentado/genética , Nevo Pigmentado/imunologia , Nevo Pigmentado/metabolismo , Nevo Pigmentado/patologia , RNA Mensageiro/biossíntese , RNA Neoplásico/biossíntese , Proteínas Recombinantes/farmacologia , Reação em Cadeia da Polimerase Via Transcriptase Reversa , Neoplasias Cutâneas/genética , Neoplasias Cutâneas/imunologia , Neoplasias Cutâneas/patologia , Células Tumorais Cultivadas/metabolismo , Receptor fas/genética , Receptor fas/fisiologia
3.
J Invest Dermatol ; 115(2): 141-8, 2000 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-10951228

RESUMO

Death receptors are a growing family of transmembrane proteins that can detect the presence of specific extracellular death signals and rapidly trigger cellular destruction by apoptosis. Expression and signaling by death receptors and their respective ligands is a tightly regulated process essential for key physiologic functions in a variety of organs, including the skin. Several death receptors and ligands, Fas and Fas ligand being the most important to date, are expressed in the skin and have proven to be essential in contributing to its functional integrity. Recent evidence has shown that Fas-induced keratinocyte apoptosis in response to ultraviolet light, prevents the accumulation of pro-carcinogenic p53 mutations by deleting ultraviolet-mutated keratinocytes. Further- more, there is strong evidence that dysregulation of Fas expression and/or signaling contributes to the pathogenesis of toxic epidermal necrolysis, acute cutaneous graft versus host disease, contact hypersensitivity and melanoma metastasis. With these new developments, strategies for modulating the function of death receptor signaling pathways have emerged and provided novel therapeutic possibilities. Specific blockade of Fas, for example with intravenous immunoglobulin preparations that contain specific anti-Fas antibodies, has shown great promise in the treatment of toxic epidermal necrolysis and may also be useful in the treatment acute graft versus host disease. Likewise, induction of death signaling by ultraviolet light can lead to hapten-specific tolerance, and gene transfer of Fas ligand to dendritic cells can be used to induce antigen specific tolerance by deleting antigen-specific T cells. Further developments in this field may have important clinical implications in cutaneous disease.


Assuntos
Apoptose/fisiologia , Receptores do Fator de Necrose Tumoral/fisiologia , Dermatopatias/fisiopatologia , Fenômenos Fisiológicos da Pele , Animais , Humanos , Isoformas de Proteínas/fisiologia
4.
J Invest Dermatol ; 112(3): 290-6, 1999 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-10084304

RESUMO

Clusterin is a widely expressed, well conserved, secreted glycoprotein, which is highly induced in tissues regressing as a consequence of apoptotic cell death in vivo. It has recently been shown that clusterin expression is only confined to surviving cells following the induction of apoptosis in vitro, suggesting that it is involved in cell survival rather than death. In the hypothesis that clusterin may be implicated in cellular responses to stress, clusterin gene expression was analyzed in the A431 human epidermoid cancer cell line following heat shock and oxidative stress. Our results show that both a transient heat shock (20 min at 42 degrees C) and various oxidative stresses, including hydrogen peroxide, superoxide anion, hyperoxia and UVA exposure, induce a strong increase in clusterin mRNA levels as assessed by northern blot. Nuclear run-on analysis suggests that transcriptional activation is involved in inducing clusterin mRNA in response to heat shock. Using pulse-chase analysis of control and heat shocked cells, it is shown that clusterin mRNA is translated and secreted, thus resulting in increased extracellular levels of the protein following heat shock. To investigate the function of clusterin in response to these stresses, clusterin anti-sense transfectants that stably express virtually no clusterin at the mRNA and protein level were generated in A431 cells. These anti-sense transfectants are shown to be highly sensitive to apoptotic cell death induced by heat shock or oxidative stress compared with wild-type A431 cells or control transfectants. Taken together, our results show that clusterin gene expression is induced in response to heat shock and oxidative stress in human A431 cells, and confers cellular protection against heat shock and oxidative stress.


Assuntos
Apoptose/fisiologia , Expressão Gênica/fisiologia , Glicoproteínas/genética , Temperatura Alta , Chaperonas Moleculares , Estresse Oxidativo/fisiologia , Choque/fisiopatologia , Clusterina , Glicoproteínas/metabolismo , Humanos , Estresse Oxidativo/genética , Choque/patologia , Transcrição Gênica/fisiologia , Transfecção/fisiologia , Células Tumorais Cultivadas
5.
Science ; 282(5388): 490-3, 1998 Oct 16.
Artigo em Inglês | MEDLINE | ID: mdl-9774279

RESUMO

Toxic epidermal necrolysis (TEN, Lyell's syndrome) is a severe adverse drug reaction in which keratinocytes die and large sections of epidermis separate from the dermis. Keratinocytes normally express the death receptor Fas (CD95); those from TEN patients were found to express lytically active Fas ligand (FasL). Antibodies present in pooled human intravenous immunoglobulins (IVIG) blocked Fas-mediated keratinocyte death in vitro. In a pilot study, 10 consecutive individuals with clinically and histologically confirmed TEN were treated with IVIG; disease progression was rapidly reversed and the outcome was favorable in all cases. Thus, Fas-FasL interactions are directly involved in the epidermal necrolysis of TEN, and IVIG may be an effective treatment.


Assuntos
Apoptose , Imunoglobulinas Intravenosas/uso terapêutico , Queratinócitos/patologia , Síndrome de Stevens-Johnson/terapia , Receptor fas/fisiologia , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Anticorpos Bloqueadores/imunologia , Anticorpos Bloqueadores/uso terapêutico , Criança , Derme/patologia , Progressão da Doença , Epiderme/patologia , Proteína Ligante Fas , Feminino , Humanos , Células Jurkat , Queratinócitos/metabolismo , Masculino , Glicoproteínas de Membrana/metabolismo , Pessoa de Meia-Idade , Projetos Piloto , Síndrome de Stevens-Johnson/patologia , Receptor fas/imunologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...